C-Bridge Capital
AVCJ Awards 2019: Deal of the Year - Small Cap: AffaMed Therapeutics
CBC Group established biosimilars specialist AffaMed Therapeutics to remove uncertainties in the development process and to tap Chinese demand for affordable treatments
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
China's I-Mab Biopharma pursues US IPO
I-Mab Biopharma, the product of a CBC Group-engineered merger of two Chinese drug developers, has announced plans for a NASDAQ IPO.
China healthcare AI: A learning process
Most healthcare-focused artificial intelligence start-ups in China focus on image-based diagnosis assistance, but deep learning-based drug discovery might be the key application
C-Bridge closes third healthcare fund at $850m
C-Bridge Capital has closed its third healthcare fund - which covers Asia but is most active in China - at $850 million, after increasing the hard cap. It is the largest dedicated healthcare vehicle raised for deployment in Asia by an independent private...
Asia GP-led secondaries hit record high in 2018
An increase in GP-led transactions propelled Asia secondary market volume to $7.8 billion last year, and more of the same is expected in 2019 – once managers have adjusted their mark-to-market valuations following fourth-quarter volatility in the public...
C-Bridge helps Korea's Samsung Bioepis with China expansion
C-Bridge Capital has announced a licensing agreement with Samsung Bioepis that is intended to help the Korean biopharmaceutical specialist expand into the China market.
C-Bridge hits $400m first close on China healthcare fund
C-Bridge Capital has reached a first close of just over $400 million on its third healthcare fund, which focuses on Chinese pharmaceutical, medical technology and healthcare services companies with proven products and technologies.
C-Bridge leads $20m round for China's Nuance
C-Bridge Capital, a Chinese healthcare-focused private equity firm, has led a $20 million Series B funding round for domestic pharmaceuticals developer Nuance Biotech.
Hong Kong technology IPOs: Size matters
Hong Kong has altered its IPO regime to attract tech companies with unorthodox shareholding structures and biotech start-ups with no revenue. But only certain businesses are welcome to apply
Chinese drug developer Ascletis files for landmark HK IPO
Ascletis, a Chinese drug developer that has received funding from C-Bridge Capital, has filed for an IPO in Hong Kong. It is set to be the first listing in the territory under new rules that allow companies with zero revenue or profit to go public.
China's CMAB Biopharma gets $34m Series B
CD Capital, a Chinese healthcare-focused VC also known as CDBI Partners, has led a $34 million Series B round for CMAB Biopharma, a manufacturing services provider for biologic product developers.
Healthcare funds: Repeat prescription
An assortment of healthcare-focused GPs – most of them in China – have emerged to leverage rising domestic consumption and nascent medical innovation. Does domain expertise mean better deal access?
C-Bridge hires ex-GSK executive as senior partner
C-Bridge Capital, a Chinese healthcare-focused private equity firm, has appointed Abbas Hussain, who was most recently global president for pharmaceuticals and vaccines at GlaxoSmithKline (GSK), as a senior partner.
C-Bridge closes second China healthcare fund at $400m
C-Bridge, a Chinese private equity firm that concentrates on late-stage growth capital and buyout opportunities in the healthcare space, has closed its second fund at the hard cap of $400 million.
PE investors back $402m Sinovac take-private
A consortium of private equity investors has agreed to privatize US-listed Chinese biopharmaceutical player Sinovac Biotech in a deal worth $401.8 million, bringing a contentious bidding process to an end.
China genomics: Coded messages
Investors are looking to tap the massive potential of China’s genomic industry, with a particular focus on companies that leverage large amounts of patient data to support drug development and testing services
C-Bridge backs China pharma merger
China healthcare-focused GP C-Bridge Capital and Tasly Holding, a traditional Chinese medicine business, have agreed to invest $150 million in a newly-created entity formed through the merger of two local pharmaceutical companies.
Deal focus: C -Bridge brings more co-investment to Ascletis
C-Bridge Capital participates in a $100 million Series B round of funding for biotechnology Ascletis alongside existing backer Goldman Sachs and a number of its LPs
C-Bridge buys control of China’s Anrei Medical
Healthcare-focused PE firm C-Bridge Capital has acquired a controlling stake in Anrei Medical Device, a China-based invasive medical devices manufacturer, for $25 million.
C-Bridge leads $100m round for China's Ascletis
Healthcare-focused PE firm C-Bridge Capital has led a Series B round of funding worth $100 million for Ascletis, a Chinese biotechnology company that specializes in treatments for liver disease.